Cancer News and Discussions

User avatar
Yuli Ban
Posts: 4631
Joined: Sun May 16, 2021 4:44 pm

Re: Cancer News and Discussions

Post by Yuli Ban »

Germany-based BioNTech announced the first patient had been treated in its BNT111 cancer vaccine
Germany-based BioNTech SE announced the first patient had been treated in its BNT111 Phase 2 cancer vaccine trial. The study evaluates the Company’s therapeutic cancer vaccine candidate BNT111 in combination with Libtayo® (cemiplimab) in patients with anti-PD1-refractory/relapsed unresectable Stage III-IV melanoma.

BNT111 is the lead product candidate from BioNTech’s FixVac platform that targets a fixed combination of mRNA-encoded, tumor-associated antigens with the objective of triggering a strong and precise immune response against cancer.

BNT111 is an intravenous therapeutic cancer vaccine candidate encoding for a fixed set of four cancer-specific antigens optimized for immunogenicity and delivered as an RNA-lipoplex formulation.

The BNT111-01 trial, which is being conducted in collaboration with Regeneron, was reviewed and approved by the regulatory authorities in Spain, Germany, Italy, Poland, and the United Kingdom, the USA, Australia.
And remember my friend, future events such as these will affect you in the future
User avatar
Yuli Ban
Posts: 4631
Joined: Sun May 16, 2021 4:44 pm

Re: Cancer News and Discussions

Post by Yuli Ban »

And remember my friend, future events such as these will affect you in the future
weatheriscool
Posts: 12967
Joined: Sun May 16, 2021 6:16 pm

Re: Cancer News and Discussions

Post by weatheriscool »

Derivative of vitamin A enhances the tumor-killing effectiveness of radiotherapy

by Kristin Rattini, University of Chicago Medical Center
https://medicalxpress.com/news/2021-06- ... erapy.html
Radiotherapy is a crucial component in cancer treatment, used in 50 to 60 percent of patients with cancer. It is traditionally used for localized cancers—such as head and neck, cervical, prostate, lung and brain cancers—with varying degrees of success.

A University of Chicago Medicine Comprehensive Cancer Center researcher-led team has discovered that combining radiotherapy with all-trans retinoic acid (ATRA) significantly inhibits the growth of not only locally irradiated tumors, but also distal tumors not treated with radiation. The combination treatment of radiation and ATRA modulates the tumor microenvironment and enhances the effects of radiation on both the local and systemic levels.

"Our group is the first to combine ATRA with radiation to treat solid tumors in animal models," said Ralph Weichselbaum, MD, Daniel K. Ludwig Distinguished Service Professor and chair of Radiation and Cellular Oncology and a senior author of the study, published in the June 11, 2021 issue of Science Immunology.
User avatar
Yuli Ban
Posts: 4631
Joined: Sun May 16, 2021 4:44 pm

Re: Cancer News and Discussions

Post by Yuli Ban »



And remember my friend, future events such as these will affect you in the future
User avatar
Yuli Ban
Posts: 4631
Joined: Sun May 16, 2021 4:44 pm

Re: Cancer News and Discussions

Post by Yuli Ban »


And remember my friend, future events such as these will affect you in the future
User avatar
raklian
Posts: 1747
Joined: Sun May 16, 2021 4:46 pm
Location: North Carolina

Re: Cancer News and Discussions

Post by raklian »

I still stand by my assertion that self-propelled, intelligent nanobots are the best way to effectively destroy tumors or cancers without upsetting the body's homeostasis.
To know is essentially the same as not knowing. The only thing that occurs is the rearrangement of atoms in your brain.
weatheriscool
Posts: 12967
Joined: Sun May 16, 2021 6:16 pm

Re: Cancer News and Discussions

Post by weatheriscool »

Drug doubles down on bone cancer and metastasis
https://medicalxpress.com/news/2021-06- ... tasis.html
by Mike Williams, Rice University

Bone cancer is hard to treat and prone to metastasis. Research teams at Rice University and Baylor College of Medicine have a new strategy to attack it.

Chemist Han Xiao at Rice and biologist Xiang Zhang at Baylor and their labs have developed an antibody conjugate called BonTarg that delivers drugs to bone tumors and inhibits metastasis.

Their open-access study, which appears in Science Advances, shows how Xiao's pClick technology can be used to link bone-targeting antibodies and therapeutic molecules.

In experiments, they used pClick to couple a molecule used to treat osteoporosis, alendronate, with the HER2-targeting antibody trastuzumab used to treat breast cancer, and found it significantly enhanced the concentration of the antibody at tumor sites.
User avatar
Yuli Ban
Posts: 4631
Joined: Sun May 16, 2021 4:44 pm

Re: Cancer News and Discussions

Post by Yuli Ban »

BioNTech Now Aims Its mRNA Technology at Cancer
Buoyed by the success of its mRNA technology against COVID-19, BioNTech is now focused on its cancer vaccines. The company recently began dosing patients for its Phase II trial for an advanced melanoma vaccine in the European Union.

BioNTech calls itself a "next-generation immunotherapy company pioneering in therapies for cancer and other serious diseases." The COVID-19 vaccine was a minor detour for the company. The company’s product pipeline is filled with mRNA vaccines targeting different types of cancers, most of which are in preclinical stages. BioNTech recently began the Phase II trial of BNT111, which will test its mRNA vaccine in combination with an antibody-drug, Libtayo, in patients with anti-PD1-relapsed Stage III/ IV melanoma. Libtayo is the commercial name for cemiplimab, co-developed by Regeneron and Sanofi, and is an anti-PD-1 monoclonal antibody.

BNT111 encodes four tumor-associated antigens: NY-ESO-1, MAGE-A3, tyrosinase, and TPTE. BioNTech claims that 90% of melanoma patients express at least one of these antigens. BNT111 is one of the many cancer vaccine candidates designed by BioNTech under its FixVac platform. FixVac consists of a fixed combination of mRNA encoded tumor-specific antigens delivered to specifically target dendritic cells. By evoking a strong immune response against these antigens, FixVac candidates help the body target cancerous cells that overexpress these antigens.
And remember my friend, future events such as these will affect you in the future
User avatar
Yuli Ban
Posts: 4631
Joined: Sun May 16, 2021 4:44 pm

Re: Cancer News and Discussions

Post by Yuli Ban »

Blood test [from Grail] that finds 50 types of cancer is accurate enough to be rolled out
A simple blood test that can detect more than 50 types of cancer before any clinical signs or symptoms of the disease emerge in a person is accurate enough to be rolled out as a screening test, according to scientists.

The test, which is also being piloted by NHS England in the autumn, is aimed at people at higher risk of the disease including patients aged 50 or older.

It is able to identify many types of the disease that are difficult to diagnose in the early stages such as head and neck, ovarian, pancreatic, oesophageal and some blood cancers.
And remember my friend, future events such as these will affect you in the future
weatheriscool
Posts: 12967
Joined: Sun May 16, 2021 6:16 pm

Re: Cancer News and Discussions

Post by weatheriscool »

Sleeper cells: Newly discovered stem cell resting phase could put brain tumors to sleep
https://medicalxpress.com/news/2021-06- ... -cell.html
by Arizona State University
Christopher Plaisier, an assistant professor of biomedical engineering in the Ira A. Fulton Schools of Engineering at Arizona State University, and Samantha O'Connor, a biomedical engineering doctoral student in the Plaisier Lab, are leading research into a new stage of the stem cell life cycle that could be the key to unlocking new methods of brain cancer treatment. Their work was recently published in the research journal Molecular Systems Biology.

"The cell cycle is such a well-studied thing and yet here we are looking at it again for the umpteenth time and a new phase pops out at us," Plaisier says. "Biology always has new insights to show us, you just have to look."

The spark for this discovery came through a collaboration with Patrick Paddison, an associate professor at the Fred Hutchinson Cancer Research Center in Seattle, and Dr. Anoop Patel, an assistant professor of neurological surgery at the University of Washington who is also involved in the Fred Hutchinson Cancer Research Center.
Post Reply